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6/j.bGraft-versus-host disease (GVHD) following bone marrow transplantation (BMT) is mediated by alloreactive
donor T lymphocytes. Migration and activation of donor-derived T lymphocytes play critical roles in the de-
velopment of GVHD. Leukocyte function–associated antigen-1 (LFA-1) regulates T cell adhesion and activa-
tion. We previously demonstrated that the I-domain, the ligand-binding site of LFA-1, changes from the
low-affinity state to the high-affinity state on LFA-1 activation. Therapeutic antagonists, such as statins, inhibit
LFA-1 activation and immune responses by modulating the affinity state of the LFA-1 I-domain. In the present
study, we report that lovastatin blocked mouse T cell adhesion, proliferation, and cytokine production in vi-
tro. Furthermore, blocking LFA-1 in the low-affinity state with lovastatin reduced the mortality and morbidity
associated with GVHD in a murine BMT model. Specifically, lovastatin prevented T lymphocytes from homing
to lymph nodes and Peyer’s patches during the GVHD initiation phase and after donor lymphocyte infusion
(DLI) after the establishment of GVHD. In addition, treatment with lovastatin impaired donor-derived T cell
proliferation in vivo. Taken together, these results indicate the important role of lovastatin in the treatment of
GVHD.
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Graft-versus-host disease (GVHD) is the primary
cause of morbidity and mortality in patients after
bone marrow transplantation (BMT), and thus a major
obstacle to the cure of various malignant and nonma-
lignant disorders. GVHD is characterized by epithelial
cell injury in skin, intestine, and liver, but has beenion of Transplantation Immunology, Department of
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bmt.2009.08.013observed, albeit less frequently, in other organs as
well, including the eye and lung [1,2]. Although allor-
eactive T cells are the primary mediators of GVHD,
the regulatory mechanisms controlling T cell activa-
tion in GVHD are not well understood [3]. Murine
models of GVHD are well established, and the disease
mechanisms and preclinical studies in this system have
been vigorously pursued [4,5].
The leukocyte function–associated antigen (LFA-
1) is an important integrin in the regulation of leuko-
cyte adhesion and T cell activation [6,7]. LFA-1 is
a heterodimer, consisting of the aL (CD11a) and b2
(CD18) subunits expressed on T cells. The ligands
for LFA-1, including intercellular adhesion molecule
(ICAM)-1, ICAM-2, and ICAM-3, are expressed on
endothelium and antigen-presenting cells [6]. LFA-1
is constitutively expressed on the surface of leukocytes
in an inactive state. Activation of LFA-1 is mediated
by signals from the cytoplasm, including the G-
protein–coupled chemokine receptor signal pathway
[6,8]. Subsequently, activated LFA-1 binds to ligands
and transduces signals back into the cytoplasm, result-
ing in cell adhesion and activation [9,10]. LFA-1
activation is a critical event in the formation of the1513
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tion synergistically with TCR engagement [7]. Mice
deficient in LFA-1 exhibit defects in leukocyte adhe-
sion, lymphocyte proliferation, and tumor rejection
[11-13]. LFA-1–blocking antibodies have been shown
to prevent autoimmunity, organ graft rejection, and
GVHD in mice and humans [14-19].
Control of LFA-1 activation is critical in inflam-
matory and immune responses. The mechanisms of
LFA-1 activation involve conformational changes
within the molecule and receptor clustering [20-22].
The I-domain of the LFA-1 aL subunit is a ligand-
binding site that changes conformation on activation
[23,24]. We previously showed that a change in the
I-domain from the low-affinity state to the high-
affinity state led to an increased affinity for ligand
binding [25-28]. We also identified antibodies that
are sensitive to the affinity changes in the I-domain
of LFA-1 and showed that the activation-dependent
epitopes were exposed on T cell activation [27,28].
Taken together, these findings demonstrate that the
I-domain of LFA-1 changes to the high-affinity state
during T cell activation.
Several lines of evidence have demonstrated that
therapeutic antagonists can inhibit LFA-1 activation
by regulating conformation changes in the I-domain
[29-31]. Lovastatin belongs to the 3-hydroxy-3-meth-
ylglutaryl coenzyme A (HMG-CoA) class of reductase
inhibitors (statins). Statins are commonly prescribed to
lower plasma cholesterol levels and thereby reduce the
risk of cardiovascular disease; however, clinical studies
involving transplant recipients have indicated a possi-
ble immunosuppressive action of statins. A newly re-
ported property of statins entirely unrelated to
HMG-CoA reductase inhibition accounts for the im-
munomodulatory effects of these compounds [31].
Lovastatin has been shown to inhibit the interaction
of LFA-1 and its ligands. Rather than interfere directly
with the binding of LFA-1 to ICAM-1, statins bind to
the L-site (lovastatin site) of the LFA-1 I-domain. The
L-site is distant from the metal ion–dependent adhe-
sion site (MIDAS), which is critical for LFA-1 binding
to its ligand ICAM-1. Thus, lovastatin stabilizes
the I-domain in the low-affinity state and inhibits
LFA-1 activation.
In the present study, we found that blocking LFA-
1 in the low-affinity state with lovastatin can block
mouse T cell adhesion and proliferation, and also
prevent GVHD in the C57BL/6 to Balb/C BMT
model. To fully assess the role of LFA-1 affinity
regulation in the development of GVHD, we exam-
ined whether blocking LFA-1 in a low-affinity state
with lovastatin affects T cell trafficking and activation.
We found that lovastatin prevented T cell homing to
secondary lymphoid organs and significantly reduced
donor-derived T cell proliferation in the mouse
BMT model.MATERIALS AND METHODS
Animals and Reagents
C57BL/6 (B6; H-2b) and BALB/c (H-2d) mice
were purchased from the Animal Production Area at
NCI-Frederick, (Frederick, MD). LFA-1–deficient
mice (LFA-12/2, C57BL/6 background) were kindly
provided by Dr Christie Ballantyne (Baylor College
of Medicine). Lovastatin and pravastatin were pur-
chased from EMD Biosciences (San Diego, CA). The
hydrolyzed sodium powder was dissolved in DMSO
and stored as recommended by the manufacturer.
The animal experiments are approved by University
of Texas M.D. Anderson Cancer Center’s Institutional
Animal Care and Use Committee.
T Cell Isolation
Single-cell suspensions were prepared from spleen
and lymph nodes of C57BL/6 mice and CD11a knock-
out mice by standard methods. T cells were purified
using the Mouse T Lymphocyte Enrichment Set-DM
(BD Biosciences San Diego, CA). In brief, 5 mL of a
biotin-antibody cocktail including biotin-conjugated
monoclonal antibodies (mAbs) against CD11b (M1/
70), CD45R/B220 (RA3-6B2), CD49b (HMa2) and
TER-119/erythroid cells (TER-119) was mixed with
1106 cells for 10 minutes on ice. Then 5 mL of the
BDTM IMag Streptavidin Particles Plus-DM were
added to the single-cell suspension, and T cells were
negatively selected with the BDTM IMagnet.
Static Adhesion Assay
Purified mouse recombinant ICAM-1/FC (R&D
Systems, Minneapolis, MN) was coated on flat-
bottomed 96-well plates, and nonspecific binding sites
were blocked with 1% bovine serum albumin. Primary
mouse lymphocytes were loaded into ICAM-1–coated
wells in the presence of Mn11 for 30 minutes at room
temperature, after which the unbound cells were re-
moved by washing. The bound cells were counted un-
der a microscope in representative fields.
Mixed Lymphocyte Culture
The experiment was performed in 96-well micro-
titer plates (Costar; Sigma-Aldrich, St Louis, MO).
C57BL/6 responder cells were plated at 1106 cells/
mL in a volume of 200 mL/well and co-cultured with
3400-cGy irradiated stimulator cells from Balb/C
mice at a ratio of 2:1. Culture supernatants were col-
lected to evaluate IL-2, TNF-a, and IFN-g produc-
tion. Proliferation was assayed on day 3 by adding
[3H]-thymidine to the culture for the final 8 hours.
GVHD Induction
The major histocompatibility complex (MHC)
class I and II disparate model, C57BL/6 (H-2b) to
Biol Blood Marrow Transplant 15:1513-1522, 2009 1515Lovastatin Prevents GHVD in a BMT Mouse ModelBalb/C (H-2d), was used to establish GVHD [4]. All re-
cipients were age-matched females aged 2-6 months at
the time of BMT. The single-cell suspensions of bone
marrow (BM) cells and splenocytes were prepared in
PBS for injection. To generate BMT chimeras, recipi-
ent Balb/C mice received 11 Gy of total body irradia-
tion (137Cs source), split into 2 doses. The mice then
received cells from donor C57BL/6 mice: 5106
BM cells (WT) and 5106 splenocytes (WT or
LFA-12/2). Survival and clinical signs of GVHD (eg,
hair loss, hunched back, diarrhea) were monitored
daily. For histopathologic analysis of GVHD target tis-
sues, samples were collected from skin, liver, intestine,
and lung and then fixed in 10% formalin. The pre-
served tissue samples were embedded in paraffin,
sectioned, and stained with hematoxylin and eosin for
histological examination. Tissue slides were systemati-
cally examined and evaluated by pathologists.In Vivo Homing Assay
Splenocytes from C57BL/6 mice were isolated and
labeled with carboxyfluorescein diacetate succinimidyl
ester (CFSE) as described previously [28]. A total of
2107 cells were transferred into mice on the same
day of transplantation immediately after statin treat-
ment. At 2 hours after the transfer, the recipient
mice were sacrificed, and peripheral and mesenteric
lymph nodes, Peyer’s patches, spleen, and blood
were harvested. The total numbers of each subset in-
jected and recovered from tissues were analyzed using
a BD Biosciences FACScan flow cytometer. The follo-
wing monoclonal antibodies were used: anti-CD4
(H129.19), anti-CD8 (53-6.7), anti-H-2Db (KH95),
anti-CD44 (IM7), anti-CD69 (H1.2F3), and anti-
CD25 (PC61) (all from BD Biosciences). Data were
collected and analyzed with CELLQuest software
(BD Biosciences).In Vivo Proliferation Assay
For the measurement of donor T cell proliferation
in vivo, splenocytes from C57BL/6 mice were isolated
and labeled with CFSE as described previously [28].
CFSE-labeled splenocytes were infused into recipient
mice with BM cells as described previously for GVHD
induction. The recipient mice were sacrificed at 3, 4, or
5 days after infusion. The cells harvested from tissues
were analyzed by flow cytometry. The cell prolifera-
tion models and cell division index were generated
using FlowJo software (Tree Star, Ashland, OR).Statistical Analysis
Survival data were plotted using the Kaplan-Meier
method and analyzed by the log-rank test. A P value of
#.05 was considered statistically significant.RESULTS
Lovastatin Inhibits Adhesion, Proliferation, and
Cytokine Production of Mouse T Cells In Vitro
An earlier study found that lovastatin, but not pra-
vastatin, inhibited the interaction of LFA-1 and
ICAM-1 in vitro, preventing adhesion and prolifera-
tion of human CD41T cells [31]. The inability of pra-
vastatin to prevent LFA-1 and ICAM-1 binding stems
from its low binding affinity for the L-site of LFA-1—
about 50-fold less than that of lovastatin. In the present
study, we further investigated whether lovastatin can
block the adhesion and proliferation of mouse T cells.
The experiments were designed to compare T cells
from the following 4 groups: (1) wild-type (WT):
LFA-1 WT mouse (C57BL/6 background); (2) WT
plus lovastatin treatment: blocking LFA-1 in the low-
affinity state and HMG-CoA reductase inhibitor; (3)
WT plus pravastatin treatment: HMG-CoA reductase
inhibitor alone; and (4) LFA-12/2: deletion of mouse
CD11a (C57BL/6 background).
The binding of primary mouse T cells to ICAM-1
was examined using the static adhesion assay. As shown
in Figure 1A, treatment with lovastatin at a concentra-
tion of 10 mM significantly inhibited WT lymphocyte
adhesion to ICAM-1 and had a similar effect on LFA-
12/2 cells, with about 27% and 18% cells, respectively,
remaining bound to ICAM-1. Pravastatin treatment
did not appear to have any significant effect on LFA-
1 mediated adhesion. We also investigated whether
blocking LFA-1 in the low-affinity state using lova-
statin would inhibit T cell proliferation and cytokine
production in a mixed lymphocyte reaction, in which
responder cells from C57BL/6 mice were plated with
irradiated stimulator cells from Balb/C mice. As shown
in Figure 1B, lovastatin treatment significantly re-
duced the percentage of T cell proliferation to 53%
compared with WT control, whereas pravastatin ex-
hibited no inhibitory effect. In addition, the prolifera-
tion was impaired in LFA-12/2 T cells. We further
investigated the functional consequences of lovastatin
treatment on IL-2, TNF-a, and IFN-g production.
As shown in Figure 1C, the total amount of IL-2 and
IFN-g was decreased significantly in the presence of
lovastatin, while the amount of TNF-a remained the
same compared with controls. This indicates that lov-
astatin inhibits mouse T cell adhesion, proliferation,
and cytokine production in vitro.Lovastatin Treatment Reduces GVHDMortality
and Morbidity in the C57BL/6 to Balb/C BMT
Model
Lovastatin can block the adhesion and prolifera-
tion of mouse T cells, which play important roles in
the development of GVHD. We used the MHC class
I and II disparate model, C57BL/6 (H-2b) to balb/C
WT            LFA-1-/-       Lovastatin      Pravastatin
0
20
40
60
80
100
120
C
e
l
l
s
 
b
o
u
n
d
 
(
%
 
o
f
 
c
o
n
t
r
o
l
)
*
* 
0
20
40
60
80
100
120
WT LFA-1-/- Lovastatin Pravastatin
Pr
ol
ife
ra
tio
n 
(%
)
  * 
*
0
20
40
60
80
100
120
IL-2 TNF-a IFN-r
C
y
t
o
k
i
n
e
 
P
r
o
d
u
c
t
i
o
n
m
 
(
%
)
  * 
  *
A
B
C
Figure 1. Lovastatin inhibits the adhesion, proliferation, and cytokine
production of mouse T cells in vitro. (A) Blocking of mouse T cell binding
to ICAM-1 with lovastatin. Primary mouse T cells (WTor LFA-1-/-) were
activated with Mn11, and WT were preincubated with lovastatin or
pravastatin at a concentration of 10mM. Binding to ICAM-1 was measured
by counting cells adherent to thewells afterwashes. (B and C) Inhibition of
mouse T cell proliferation (B) and cytokine production (C) with lovastatin.
Column-purified C57BL/6 responder cells were plated at 1106 cells/mL
in a volume of 200 mL/well and co-cultured at a ratio of 2:1 with 3400-cGy
irradiated stimulator cells from the Balb/C mice. Proliferation was assayed
on day 3 by adding [3H]-thymidine to the culture for the final 8 hours. Pro-
duction of IL-2, TNF-a, and IFN-g in culture supernatant was measured
by ELISA after 24 hours in the presence of DMSO (black bar), lovasatin
(gray bar), and pravastatin (white bar). Results are the mean and standard
deviation of 3 independent experiments normalized to that of WT con-
trols. An asterisk indicates data with P value\ .05 in t-tests.
Figure 2. Lovastatin treatment reduces the mortality associated with
GVHD. Mice were treated with statins at the dose of 50 mg/mouse every
other day, starting on the day of BMT. The control group received vehicle
(10% DMSO in saline). Survival was monitored daily and followed up to
28 days. The data are compiled from all of the mice examined. Distribu-
tions of time to death were estimated using the Kaplan-Meier method
and compared between treatments using the log-rank test. No adjust-
ment was made for the comparisons. The results are from at least 3 in-
dependent experiments, with 3 mice per group in each experiment.
1516 Biol Blood Marrow Transplant 15:1513-1522, 2009Y. Wang et al.(H-2d), to examine whether blocking LFA-1 in the
low-affinity state using lovastatin can prevent GVHD.
For generation of BMT chimeras, irradiated recipient
balb/C mice received cells from donor C57BL/6 mice:5106 BM cells (WT) and 5106 splenocytes (WT or
LFA-12/2). The mice who received WT splenocytes
were treated with statins (sodium, hydrolyzed) at
a dose of 50 mg/mouse (2 mg/kg) via i.p. injection every
other day, starting on the same day as the BMT. The
control group received vehicle (10% DMSO in saline).
Mice were monitored daily and followed up to 28 days
(4 weeks).
As shown in Figure 2, mice began to die on day 5
post-BMT, and more than 70% of the mice died
within the first 10 days. Pravastatin failed to protect
the mice from GVHD mortality, indicating that the
HMG-CoA reductase inhibitor activity of statins had
no effect on GVHD and did not induce additional tox-
icity in this setting. In contrast, all recipients of LFA-
12/2 splenocytes survived for more than 28 days,
although the mild clinical signs of GVHD (eg, hair
loss, hunched back, diarrhea) were observed. Lova-
statin treatment led to a significant decrease in mortal-
ity, with about 75% of mice surviving for more than 28
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Figure 3. Lovastatin treatment reduces GVHD in the skin and liver. Mice were sacrificed on day 7 posttransplantation (4 mice per group). Tissues were
placed in 10% formalin, embedded in paraffin, sectioned, stained with hematoxylin and eosin, and scored for GVHD histopathology. (A) The top panels
are representative sections from the skin of mice treated with DMSO, lovastatin, and pravastatin. The skin shows moderate to severe changes consistent
with GVHD, with lymphoid infiltrates (arrow) and epidermal and adnexal cell apoptosis in the WTand pravastatin-treated mice. Only mild changes in
the skin of the lovastatin-treated mice were noted. The lower panels are representative sections from the liver. Perivascular lymphoid infilrates
(arrows) within portal triads associated with bile duct damage were noted in the livers of the WT and pravastatin-treated mice, but not of the lova-
statin-treated mice. (B) The average score of skin and liver GVHD of each group. Results are mean and standard deviation of 4 mice. An asterisk indicates
data with P value\ .05 in t-tests.
Biol Blood Marrow Transplant 15:1513-1522, 2009 1517Lovastatin Prevents GHVD in a BMT Mouse Modeldays. The P values were .008 and .02 compared with
vehicle control and pravastatin treatment, respectively.
Survival data were plotted by the Kaplan-Meier
method and analyzed using the log-rank test, with no
adjustment for the multiplicity of testing.
The skin, intestine, liver, and lung were the pri-
mary sites of GVHD. Mice from each treatment group
were sacrificed for postmortem histopathologic analy-
sis on day 7 posttransplantation after GVHD induc-
tion. As shown in Figure 3A, consistent moderate to
severe GVHD, consisting of the interface lymphoid
infiltrates and epidermal cell apoptosis, was noted in
the skin of the WT and pravastatin-treated mice.
Only mild skin changes were noted in the lovastatin-
treated mice. In addition, perivascular lymphoid infil-
trates with bile duct damage were noted in the livers of
the WT and pravastatin-treated mice, but not in those
of the lovastatin-treated mice. The lovastatin-treatedmice had significantly lower GVHD scores in both
the skin and liver (Figure 3B).Lovastatin Decreases T Cell Homing to Lymph
Nodes and Peyer’s Patches
LFA-1 is important in regulating naı¨ve T cell traf-
ficking to the secondary lymphoid organs, where they
encounter the antigen-presenting cells (APCs) for ac-
tivation. LFA-12/2 lymphocytes have profound de-
fects in homing to lymph nodes and Peyer’s patches
[13]. We examined whether lovastatin treatment can
prevent T lymphocyte homing to secondary lymphoid
organs during both the GVHD initiation phase and
following donor lymphocyte infusion (DLI) after the
establishment of GVHD.
A short-term homing assay was used to study
the trafficking pattern of statin-treated lymphocytes.
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Figure 4. Donor-derived T cell homing to the secondary lymphoid
organs. Donor-derived splenocytes were labeled with CFSE and trans-
ferred into mice on the day of BMT immediately after statin treatment.
At 2 hours after transfer, the recipient mice were sacrificed. Cells were
collected from spleen, peripheral lymph nodes, and Peyer’s patches and
then stained with CD4-PerCP, CD8-APC, and H-2Db-PE antibodies.
The number of injected T cell subsets recovered from each tissue,
CD41/H-2Db1/CFSEhi (A) and CD81/H-2Db1/CFSEhi (B), was deter-
mined by FACS. Results were calculated as the mean and SD of at least
3 independent experiments normalized to that of WT controls. An as-
terisk indicates data with P value\ .05 in t-tests.
1518 Biol Blood Marrow Transplant 15:1513-1522, 2009Y. Wang et al.Donor-derived splenocytes were labeled with CFSE
and transferred into mice immediately after statin
treatment. At 2 hours after transfer, the recipient mice
were sacrificed, and spleen, peripheral lymph nodes
and Peyer’s patches were harvested. The ratio of in-
jected T cells to recipient T cells from each tissue
sample was determined by fluorescent-activated cell
sorting (FACS). CFSE-labeled splenocytes were trans-
ferred into mice at day 0 posttransplantation immedi-
ately after statin treatment. As shown in Figure 4A, the
lovastatin treatment group exhibited an approximate
65% reduction in CD41 T cells homing to peripheral
lymph nodes compared with the pravastatin treatment
and control groups. CD81 T cell homing was reduced
even more significantly in the lovastarin treatmentgroup, with about 76% less cells homing to the periph-
eral lymph nodes in this group compared with the
controls (Figure 4B). The homing of donor-derived
T cells to Peyer’s patches was reduced with lovastatin
treatment as well, but the reduction was less pro-
nounced than that seen in lymph nodes: a 29% reduc-
tion in CD41 T cells and a 48% reduction in CD81 T
cells compared with controls (Figure 4). In contrast,
lovastatin treatment promoted both CD41 and CD81
T cell homing to the spleen, with a 32% increase in
CD41 T cell homing and a 20% increase in CD81
T cell homing compared with the controls. A similar
homing pattern to that seen in these secondary lymph
organs was found when CFSE-labeled donor spleno-
cytes were transferred on day 6 posttransplantation
(data not shown). Taken together, our findings show
that blocking LFA-1 in the low-affinity conformation
with lovastatin decreased donor T cell homing to pe-
ripheral lymph nodes and Peyer’s patches both during
the GVHD initiation phase and after the establish-
ment of GVHD.Lovastatin Reduces Donor-Derived T Cell
Proliferation In Vivo
To examine whether blocking LFA-1 in the low-
affinity state by lovastatin affects T cell proliferation,
we measured the in vivo proliferation of donor-derived
T cells using the CFSE tracking assay. GVHD induc-
tion was done as described previously, except that do-
nor C57BL/6 splenocytes were labeled with CFSE and
then infused into the irradiated Balb/C recipients
simultaneously with the BM cells. The onset of
GVHD in this model is robust and occurs within the
first 7 days posttransplantation. Mice were sacrificed
on day 3, 4, or 5 posttransplantation. Cells from spleen
and peripheral lymph nodes were stained with anti-
bodies, and the proliferation kinetics of CD41 and
CD81 T cell subsets were analyzed.
The donor-derived T cells divided rapidly in the
spleen, with the majority of cells becoming CFSE-
negative by day 3 posttransplantation, as shown in the
lower-left insert of Figure 5, which represents the do-
nor-derived (boxed, H-2Db–positive) CD41 or CD81
T cells in each plot from a different treatment group.
In the control spleen as shown in Figure 5, about
67.9% of CD41 and 97% CD81 T cells were donor-
derived. Although the homing of donor-derived T
lymphocytes to the spleen were significantly increased
in the lovastatin-treated mice compared with the con-
trols (Figure 4), the number of donor-derived CD4
and CD8 subsets was similar in the 2 groups, suggest-
ing that lovastatin reduced both CD41 and CD81 T
cell proliferation in the spleen.
The less-rapid proliferation of donor-derived T
cells in the peripheral lymph nodes than in the spleen
allowed us to analyze the proliferation kinetics of
Figure 5. Donor-derived T cell proliferation in the spleen. The in vivo proliferation of donor-derived T cells in the spleen was measured by a CFSE
tracking assay. Donor splenocytes were labeled with CFSE and then infused into the recipients with the bone marrow cells. On day 3 posttransplantation,
the mice were sacrificed, and cells from the spleens were stained with CD4-PerCP, CD8-APC, and H-2Db-PE. The CD41 T cells (A) and CD81 T cells
(B) are displayed on dot plots for the donor marker H-2Db. The percentage of donor-derived cells (CD41/H-2Db1 or CD81/H-2Db1) is noted on the
top of the boxed region, and the lower-left insert of each plot shows a CFSE histogram of this designated population. The data given here are repre-
sentative of at least 3 independent experiments.
Biol Blood Marrow Transplant 15:1513-1522, 2009 1519Lovastatin Prevents GHVD in a BMT Mouse Modeldonor-derived CD41 and CD81 T cell subsets. As
shown in Figure 6A, 37% of CD41 T cells and 31%
of CD81 T cells remained undivided in the lymph no-
des of the control mice at day 4 posttransplantation.
Lovastatin reduced the proliferation kinetics of both
CD41 and CD81 T cells, with approximately 55%
and 42% of these cells, respectively, remaining undi-
vided. Compared with CD41 T cells, for which most
of the proliferating cells were in the fifth to eighthcell division (Figure 6A, left), the CD81T cells divided
faster, with most of the proliferating cells in the
seventh to ninth cell division (Figure 6A, right). In
the control lymph nodes, 42% of the CD41 T cells
and 59% of the CD81 T cells proliferated beyond
the fifth and sixth cell divisions, respectively, whereas
lovastatin treatment reduced these respective percent-
ages to 31% and 48%; thus, the cell division index
of both the CD41 and CD81 T cells was reduced
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Figure 6. Donor-derived T cell proliferation in the peripheral lymph nodes. The in vivo proliferation of donor-derived T cells in the lymph nodes was
measured on day 4 posttransplantation using a CFSE tracking assay. Cells from lymph nodes were stained with CD4-PerCP, CD8-APC, and H-2Db-PE.
The donor-derived T lymphocyte subsets (CD41/H-2Db1 and CD81/H-2Db1) were identified by FACS. (A) The proliferation kinetics of donor-derived
CD41 (left) and CD81 (right) cells were analyzed using FlowJo. The cell proliferation models were generated based on the CFSE histogram data. The cell
division numbers are displayed on the top of each panel. The percentages of undivided cells and dividing cells are labeled. (B) Cell division indexes were
calculated using FlowJo based on the proliferation kinetics. The data shown here are representative of 3 independent experiments. An asterisk indicates
data with P value\ .05 in t-tests.
1520 Biol Blood Marrow Transplant 15:1513-1522, 2009Y. Wang et al.(Figure 6B). The proliferation kinetics of both CD41
and CD81T cells were siilar in the pravastatin-treated
mice and the control mice. Taken together, these find-
ings indicate that blocking LFA-1 in the low-affinity
state with lovastatin reduces the proliferation rate of
donor-derived CD41 and CD81 T cells in the lymph
nodes.DISCUSSION
LFA-1 plays a critical role in regulating the traf-
ficking and activation of T cells, both of which are im-
portant in the development of GVHD. In the present
study, we have found that blocking LFA-1 in the low-
affinity state with lovastatin can prevent GVHD in
a mouse model of BMT. We have demonstrated that
lovastatin can inhibit mouse T cell adhesion and pro-
liferation both in vitro and in vivo. The decreasedGVHD mortality and morbidity observed in the lova-
statin-treated mice is attributed to the decreased hom-
ing of donor T cells to secondary lymphoid organs and
consequent reduced proliferation of these cells. It has
been demonstrated previously that blocking LFA-1
with antibody reduced the severity of GVHD in
mice [17,18]. We found that all recipients of
LFA-12/2 T cells survived beyond 4 weeks, with only
mild clinical signs of GVHD. A recent study has found
that treatment of donors with atorvastatin provided
GVHD protection by Th-2 polarization while sparing
graft-versus-leukemia activity [32]. Our data further
demonstrate that LFA-1 plays an important role in
the development of mouse GVHD by regulating do-
nor T cell migration and proliferation in vivo.
LFA-1 as a therapeutic target has been investigated
extensively, and the findings have important clinical
implications [14]. Efalizumab, an LFA-1–blocking
Biol Blood Marrow Transplant 15:1513-1522, 2009 1521Lovastatin Prevents GHVD in a BMT Mouse Modelantibody, was recently approved for he treatment of
psoriasis [19]. Based on our studies, efalizumab might
be a good potential candidate for clinical trials aimed at
preventing and treating GVHD. Much remains to be
learned about the role of these LFA-1 inhibitors,
however, as evidenced by the recent voluntary market
withdrawal of the anti–LFA-1 antibody because of
viral-induced progressive multifocal leukoencephal-
opathy [33]. Recent new insights into the mechanisms
of LFA-1 activation have provided a novel approach to
targeting LFA-1. We previously demonstrated that
the affinity regulation of the I-domain is important for
LFA-1 activation [25-28]. Furthermore, lovastatin can
lock the I-domain in the low-affinity state, thereby in-
hibiting LFA-1 activation [29-31]. If the activation of
LFA-1 is essential for alloactivation of donor-derived
T cells, then blocking LFA-1 in the low-affinity state
can prevent GVHD. Indeed, our data demonstrate that
lovastatin treatment reduces GVHD in mice, with an
effect comparable to that resulting from deleting
LFA-1 in donor T cells. The use of statins might prove
clinically advantageous compared with the LFA-1–
blocking antibody approach, because lovastatin regu-
lates LFA-1 activation by modulating the affinity state
through the L-site, rather than competitively blocking
LFA-1 binding to its ligand via MIDAS.
We also have demonstrated that lovastatin reduces
the homing of both CD41 and CD81 T cells to
peripheral lymph nodes and Peyer’s patches, whereas
it increases donor-derived T cells in the spleen. This
result is similar to a previously reported finding that
LFA-1-/- lymphocytes have profound defects in hom-
ing to secondary lymphoid organs [13]. In addition,
LFA-1 regulates T cell activation via the immunolog-
ical synapse, and lovastatin prevents T cell prolifera-
tion in vitro. Because T cell activation occurs in the
secondary lymphoid organs in vivo, our results suggest
that lovastatin decreases the ability of donor-derived T
cells to enter these sites, thus limiting their prolifera-
tive capacity. Using in vivo imaging in a BMT model
similar to ours, Beilhack et al. [34] investigated the
early events involved in acute GVHD (aGVHD). They
found that donor lymphocytes infiltrated and prolif-
erated in the secondary lymphoid organs (eg, spleen,
lymph nodes, Peyer’s patches) within day 1 and inten-
sified by day 4 posttransplantation, before invading
primary target organs including the skin, gut, and
liver. We have demonstrated that lovastatin prevents
both the homing and proliferation of donor T cells in
the secondary lymphoid organs, which are crucial
sites of alloreactive expansion. Although most of the
control mice died of acute GVHD within the first
week posttransplantation, when alloreactive T cells
infiltrated the targeted organs, lovastatin treatment
prevented the activation and expansion of donor-
derived T cells, thus reducing GVHD mortality and
morbidity.Importantly, the dose of statins that we used in the
mice in our study is within the standard dosage range ap-
proved for humans. Both lovastatin and pravastatin were
well tolerated without obvious toxicity in the mouse
GVHD model. In contrast to lovastatin, pravastatin
did not appear to prevent GVHD; however, a recent
safety and efficacy study reported that pravastatin can
improve GVHD outcome in humans, although the au-
thors suggested that lovastatin may have a greater effect
in treating GVHD because of its stronger affinity for the
L-site, and thus more efficient inhibition of LFA-1 acti-
vation [35]. This is consistent with our results. To dem-
onstrate LFA-1 specificity, ideally such compounds as
LFA703, which specifically inhibits LFA-1 activation
without activity as a HMG-CoA reductase inhibitor,
should be used [31,36]. As an alternative, we used pra-
vastatin as a control, which has similar potency as lova-
statin as an HMG-CoA inhibitor but is much less potent
in blocking LFA-1 and ICAM-1 binding (pravastatin
IC50.100 mM vs lovastatin IC50 5 2.1 mM) [31]. We
demonstrated that pravastatin failed to protect the
mice from developing GVHD, thus indicating that
lovastatin’s ability to prevent GVHD results from
blocking LFA-1 activation and binding to ICAM-1.
Statins block HMG-CoA reductase at the nanomo-
lar range and LFA-1 inhibition requires higher concen-
trations, in the micromolar range [31,37]. The dose of
2 mg/kg that we used here can achieve a plasma con-
centration of approximately 1.4 mM within 1 hour,
which then declines rapidly over 24 hours, according
to published preclinical pharmacokinetic studies [38].
Although we have demonstrated the efficacy of lova-
statin in the mouse GVHD model, the concern remains
that statins may not function as effective anti-inflam-
matory reagents at the approved doses in humans.
LFA703 and other potential LFA-1 antagonists in the
pipeline might yield an improved family of statins for
treating GVHD in the near future [31,36].
In summary, our findings indicate that LFA-1
activation plays a critical role in donor-derived T cell
activation and GVHD. Our study provides new
insights into the molecular mechanisms of T cell
activation in GVHD and also provides a rationale for
a potentially novel approach to GVHD prevention
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